Archive for October 2015
Esophageal Cancer Therapeutics Market is forecast to Show High Growth Until 2017, The report identifies the key trends shaping and driving the global Esophageal Cancer Therapeutics market.
GlobalData estimates that the global esophageal cancer therapeutics market was valued at $243.8m in
2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 14% over the next seven
years, to reach $594.7m by 2017. This fast growth is primarily attributed to the strong pipeline and onset of four promising molecules from 2014 onwards. The HER-2 expressing patients have access to
Herceptin (transtuzumab) which is approved for HER2-overexpressing metastatic gastroesophageal (GE)
junction adenocarcinoma along with some widely used off-label drugs such as cisplatin and capecitabine
and ECF (epirubicin,cisplatin and 5-FU) which have gone off-patent.
GlobalData analysis shows that the esophageal cancer therapeutics pipeline is strong, with 35 molecules
in various phases of clinical development, including 31 first-in-class molecules. The four promising first-inclass products such as Avastin (bevacizumab), Erbitux (cetuximab), ramucirumab and Tykerb (lapitinib) in late stage pipeline are expected to hit the market around 2014. These products possess mechanisms of action different from currently used drugs. Thus the pipeline for the esophageal cancer therapeutics
market is strong.